Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Fineline Cube Sep 8, 2026
Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Fineline Cube Sep 8, 2026
Company Deals

Nanjing CRO Caremo Secures RMB 150 Million in Series A Round

Fineline Cube Jun 22, 2022

Nanjing-based Contract Research Organization (CRO) Caremo has reportedly secured RMB 150 million (USD 22.3 million)...

Company Drug

Lee’s Pharmaceutical Wins NMPA Approval for ALS Drug Teglutik

Fineline Cube Jun 22, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has announced receiving market approval from the National...

Company Deals Hospital

Winsan Medical Acquires 52% Stake in Goodfeel Dental Clinic for RMB 156 Million

Fineline Cube Jun 22, 2022

China-based Winsan (Chengdu) Medical Science and Technology Co., Ltd (SHA: 600767) is set to acquire...

Company Drug

InnoCare Pharma’s ICP-189 First Dosed in China SHP2 Inhibitor Trial

Fineline Cube Jun 22, 2022

Beijing InnoCare Pharma (HKG: 9969) has announced the first patient dosing in a clinical study...

Company Deals

China NT Pharma Group Inks Licensing Deal for Orticumab in Asia

Fineline Cube Jun 22, 2022

China-based China NT Pharma Group Company Ltd (HKG: 1011) has announced a licensing agreement with...

Company Deals

Mega Genomics Limited Makes Hong Kong IPO Debut at HKD 18 Per Share

Fineline Cube Jun 22, 2022

China-based gene testing platform company Mega Genomics Limited has successfully completed an initial public offering...

Company Medical Device

Venus Medtech’s VenusP-Valve Used Compassionately in US for Pulmonary Regurgitation

Fineline Cube Jun 22, 2022

Venus Medtech (Hangzhou) Inc. (HKG: 2500) announced the first compassionate use of its VenusP-Valve, a...

Company Drug

Merck KGaA’s Erbitux Approved in China for Head and Neck Cancer Treatment

Fineline Cube Jun 22, 2022

Germany-based pharmaceutical firm Merck KGaA announced that China’s National Medical Products Administration (NMPA) has issued...

Company Drug

CSPC’s JMT103 Accepted for Review in China, Targets RANKL-Related Deficiencies

Fineline Cube Jun 22, 2022

The Center for Drug Evaluation (CDE) website indicates that a market filing by China-based CSPC...

Company Medical Device

Grand Pharma Launches SIR-Spheres for Liver Cancer Treatment in China

Fineline Cube Jun 22, 2022

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the official launch of its SIR-Spheres...

Policy / Regulatory R&D

Beijing Introduces White List System for Biomedical R&D Item Imports

Fineline Cube Jun 21, 2022

Beijing has announced the introduction of a ‘white list’ system to facilitate the import of...

Company Drug

Ocumension Therapeutics’ OT-401 Approved for Chronic Non-Infectious Uveitis in China

Fineline Cube Jun 21, 2022

China-based Ocumension Therapeutics (HKG: 1477) has received approval from the National Medical Products Administration (NMPA)...

Company

AstraZeneca Expands in China with Qingdao Partnership and Manufacturing Base

Fineline Cube Jun 21, 2022

UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) is significantly expanding its presence in China through a...

Company Drug

CStone Pharmaceuticals’ Ayvakit Included in Taiwan’s National Health Insurance

Fineline Cube Jun 21, 2022

China-based CStone Pharmaceuticals (HKG: 2616) announced that its Ayvakit (avapritinib), a tyrosine kinase inhibitor for...

Company Deals

Eureka Biotechnology Secures RMB 100 Million for Cell and Gene Therapy Solutions

Fineline Cube Jun 21, 2022

Shenzhen-based Eureka Biotechnology, a company specializing in comprehensive solutions for the cell and gene therapy...

Company Deals

Therorna Secures Over RMB 280 Million in Series A Round to Accelerate circRNA Tech Development

Fineline Cube Jun 21, 2022

China-based Therorna Inc., a biotech company specializing in cutting-edge circular RNA (circRNA) technology for next-generation...

Company Medical Device

Qingdao HuaRen Pharmaceutical Gains CE Marks for Monkeypox and COVID-19 Detection Kits

Fineline Cube Jun 21, 2022

China-based Qingdao HuaRen Pharmaceutical Co., Ltd (SHE: 300110) has announced receiving CE marks in the...

Company Drug

SSY Group’s Blonanserin and Paracetamol Approved by China’s NMPA

Fineline Cube Jun 21, 2022

China-based SSY Group Limited (HKG: 2005) has announced receiving market approvals from the National Medical...

Company Deals

Shanghai ShineYo Medical Device Secures RMB 100 Million in Series A Round

Fineline Cube Jun 21, 2022

Shanghai ShineYo Medical Device Co., Ltd, a company specializing in electrophysiology and peripheral intervention, has...

Company Deals R&D

Boehringer Ingelheim Venture Fund and Hong Kong Science Park Launch Co-Incubation Plan

Fineline Cube Jun 20, 2022

Germany-based pharmaceutical giant Boehringer Ingelheim’s venture fund (BIVF) and China-based Hong Kong Science & Technology...

Posts pagination

1 … 711 712 713 … 718

Recent updates

  • Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections
  • China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback
  • Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation
  • CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally
  • Insilico Medicine Partners with Byterna Therapeutics to Build Next‑Generation mRNA AI‑Native R&D Engine – Targeting Circular mRNA Personalized Cancer Vaccines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Company Deals

Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation

Company Deals

CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.